Advertisement

Results of Chemotherapy of Malignant Brain Tumors in Adults

  • P. Krauseneck
  • H. G. Mertens

Abstract

The aim of this article is to review the results of modern chemotherapy and multiple agent trials in the treatment of malignant brain tumors in adults. As introduction a brief outline of diagnostic methods is given, and some remarks on time schedule and pecularities of follow-up examinations and treatment evaluation are made to allow a more critical appraisal of the clinical results.

Keywords

Brain Tumor Brain Metastasis Malignant Glioma Malignant Brain Tumor Leptomeningeal Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I. Aabo K, Walbom-Jorgensen S (1986) Central nervous system complications by malignant lymphomas: Radiation schedule and treatment results. J Radiat Oncol Biol Phys 12: 197–202Google Scholar
  2. 2.
    Afra D, Lazar L, Slowik F (1979) Combined treatment of medulloblastomas in adults. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier/North-Holland, pp 177–188Google Scholar
  3. 3.
    Allen JC, Bloom J, Ertel I, Evans A, Hammond D, Jones H, Levin V, Jenkin D, Sposto R, Wara W (1986) Brain tumors in children: Current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. Semin Oncol 13: 110–122Google Scholar
  4. 4.
    Andersen AP (1981) Scandinavian glioblastoma study group: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time. Cancer 47: 649PubMedGoogle Scholar
  5. 5.
    Aroney RS, Kaplan RS, Salcman M, Montgomery E, Wiernik PH (1982) A phase II trial of AZQ (NSC 182986) in patients with recurrent primary or metastatic brain tumors. Abstract, ASCO MeetingGoogle Scholar
  6. 6.
    Aronin PA, Mahaley MS jr, Rudnick SA, Dudka L, Donohue JF, Selker RG, Moore P (1980) Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. N Engl J Med 303: 183–188PubMedGoogle Scholar
  7. 7.
    Ascherl GF, Hilal SK, Brisman R (1981) Computed tomography of disseminated meningeal and ependymal malignant neoplasms. Neurology 31: 567–574PubMedGoogle Scholar
  8. 8.
    Barnett MJ, Ganesan TS, Waxman JH, Richards MA, Smith BF, Rohatiner AZS, Dhaliwal HS, Slevin ML, Lister TA (1985) Neurotoxicity of high-dose cytosine arabinoside. Prog Exp Tumor Res 29: 177–182PubMedGoogle Scholar
  9. 9.
    Bateman DE, McDermott J, Hughes DR, Edwardson JA (1986) The selective release of polypeptides from human glioma cell cultures and their possible modification by dexamethasone. Abstract, International meeting on brain oncology, Rennes, p 11Google Scholar
  10. 10.
    Behnke J, Mach JP, Buchegger F, Carrel S, Delaloye B, de Tribolet N (1986) In vivo localization of radiolabelled monoclonal antibody in human gliomas. Abstract, International meeting on brain oncology, Rennes, p 22Google Scholar
  11. 11.
    Blasberg R, Patlak C (1979) Metastatic brain tumors: local blood flow and capillary permeability. Neurology 29: 547Google Scholar
  12. 12.
    Bleyer WA, Drake JC, Chabner BA (1973) Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289: 770–773PubMedGoogle Scholar
  13. 13.
    Bleyer WA, Poplack DG, Simon RM (1978) “Concentration x Time” methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51: 835–842Google Scholar
  14. 14.
    Bloom HJG (1982) Medulloblastoma in children: Increasing survival rates and further prospects. Int J Radiat Oncol Biol Phys 8: 2023–2027PubMedGoogle Scholar
  15. 15.
    Boethius J, Blomgren H, Collins VP, Greitz T, Strander H (1983) The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir (Wien) 68: 239–251Google Scholar
  16. 16.
    Boettcher HD, Wagner W, Haverkamp U, Schadel A (1983) Zum Auftreten and zur Prognose des Medulloblastoms im Erwachsenenalter. Strahlentherapie 159: 143–146Google Scholar
  17. 17.
    Bogdahn U, Bogdahn S, Mertens HG, Dommasch D, Wodarz R, Wünsch PH, Kühl P, Richter E (1986) Primary non-Hodgkin’s lymphomas of the CNS. Acta Neurol Scand 73: 602–614PubMedGoogle Scholar
  18. 18.
    Brooks DJ, Beaney RP, Thomas DGT (1986) The role of positron emission tomography in the study of cerebral tumors. Semin Oncol 13: 83–93PubMedGoogle Scholar
  19. 19.
    Brucher JM (1983) Stereotaxic biopsies of the brain. In: Krauseneck P, Mertens HG (Hrsg) Therapie maligner Neoplasien des Gehirns. Perimed, Erlangen, S 26–28Google Scholar
  20. 20.
    Bryan P (1974) CSF seeding of intra-cranial tumours: A study of 96 cases. Clin Radio! 25: 355–360Google Scholar
  21. 21.
    Budka H, Majdic, Knapp W (1985) Cross-reactivity between human hemopoietic cells and brain tumors as defined by monoclonal antibodies. J Neuro-Oncol 3: 173–179Google Scholar
  22. 22.
    Burger PC, Dubois PJ, Schold SC jr, Smith KR jr, Odom GL, Crafts DC, Giangaspero F (1983) Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58: 159–169PubMedGoogle Scholar
  23. 23.
    Burger PC (1983) Pathologic anatomy and CT correlations in the glioblastoma multiforme. Appl Neurophysiol 46: 180–187PubMedGoogle Scholar
  24. 24.
    Burger PC, Vogel FS, Green SB, Strike TA (1985) Glioblastoma multiforme and anaplastic astrocytoma. Cancer 56: 1106–1111PubMedGoogle Scholar
  25. 25.
    Burger PC (1986) Malignant astrocytic neoplasms: Classification, pathologic anatomy, and response to treatment. Semin Oncol 13: 16–26PubMedGoogle Scholar
  26. 26.
    Byar DP, Green SB, Strike TA (1983) Prognostic factors for malignant glioma. In: Walker MD (ed) Oncology of the nervous system. M Nijhoff, Boston, pp 379–396Google Scholar
  27. 27.
    Cairncross JG, Chernik NL, Kimm JH, Posner JB (1979) Sterilization of cerebral metastases by radiation therapy. Neurology 29: 1195–1202PubMedGoogle Scholar
  28. 28.
    Cairncross JG, Posner JB (1983) The management of brain metastases. In: Walker MD (ed) Oncology of the nervous system. M Nijhoff, Boston, pp 341–378Google Scholar
  29. 29.
    Cascino TL, Byrne TN, Deck MDF, Posner JB (1983) Intraarterial BCNU in the treatment of metastatic brain tumors. J Neuro-Oncol 1: 211–218Google Scholar
  30. 30.
    Carey RW, Davis JM, Zervas NT (1981) Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treat Rep 65: 793–795PubMedGoogle Scholar
  31. 31.
    Casimir M, Yap HY, di Stefano A, Hortobagyi GN, Blumenschein GR (1981) The influence of combined modality treatment on the survival of breast cancer patients with brain metastases. ASCO Abstracts, C-427Google Scholar
  32. 32.
    Chan PYM, Byfield JE, Campbell T, Sladoff L, Rao AR (1980) Combined chemotherapy and irradiation in the treatment of brain metastases from lung cancer. In: Weiss E, Gilbert HA, Posner JB (eds) Brain metastasis. Hall, BostonGoogle Scholar
  33. 33.
    Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997–1007PubMedGoogle Scholar
  34. 34.
    Chatel M (1986) EORTC chemotherapeutic trials in malignant brain gliomas. Abstract 14th Int Cancer Congr, Budapest, p 294Google Scholar
  35. 35.
    Cohen ME, Duffner PK (1984) Brain tumors in children. Raven Press, New YorkGoogle Scholar
  36. 36.
    Colomer R, Fuentes R, Boada M, Rubio D (1986) Regression of brain metastases from breast cancer with tamoxifen. Abstr 14th Int Cancer Congr, Budapest, p 470Google Scholar
  37. 37.
    Conte PF, Guerrasio A, Bumma C, Giaccome C, Musella R, Lombard GF, Distefano FF, Calciati A (1982) VM 26, adriamycine and CCNU combination chemotherapy in metastatic brain tumours. In: Hildebrand D, Gangji D (eds) Treatment of neoplastic lesions of the nervous system. Pergamon Press, Oxford New York, pp 161–164Google Scholar
  38. 38.
    Curt GA, Schilsky R, Kelly J, Kufta C, Smith B, Thomas C, Young RC (1982) Phase II study of aziridinylbenzoquinone (AZQ) in high grade gliomas. Abstract, ASCO meetingGoogle Scholar
  39. 39.
    Darling JL, Bradley NJ, Pilkington GJ, Lantos PL, Thomas DGT (1984) Differential effects of human leukocyte (IFN-gamma) and fibroblast ( IFN-beta) derived interferons on human glioma cell cultures in vitro. Neuropathol Appl Neurobiol 10: 309Google Scholar
  40. 40.
    Decker DA, Sarraf MA, Kresge C, Austin D, Wilner HI (1985) Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. J Neuro-Oncol 3: 19–21Google Scholar
  41. 41.
    Di Chiro G (1985) Brain imaging of glucose utilization in cerebral tumors. In: Sokoloff L (ed) Brain imaging and brain function. Raven Press, New York, pp 185–197Google Scholar
  42. 42.
    Djerassi I, Kim JS, Reggev A (1985) Response of astrocytoma to high-dose methotrexate with citrovorum factor rescue. Cancer 55: 2741–2747PubMedGoogle Scholar
  43. 43.
    Dommasch D, Przuntek H, Grüninger W, Mertens HG (1976) Intrathecal cytostatic chemotherapy of meningitis carcinomatosa. Eur Neurol 14: 178PubMedGoogle Scholar
  44. 44.
    Donoso JA, Samson F (1984) Mechanisms of neurotoxicity of anticancer drugs. In: Blum K, Manzo L (eds) Neurotoxicology. Marcel Dekker, New York BaselGoogle Scholar
  45. 45.
    Duff TA, Borden E, Bay J, Phepmeier J, Sielaff K (1986) Phase II trial of interferon-I3 for treatment of recurrent glioblastoma multiforme. J Neurosurg 64: 408–413PubMedGoogle Scholar
  46. 46.
    Ehya H, Hajdu SI, Melamed MR (1981) Cytopathology of non lymphoreticular neoplasms metastatic to the central nervous system. Acta Cytol 25 /6: 599–610PubMedGoogle Scholar
  47. 47.
    E.O.R.T.C. Brain Tumor Group (1976) Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma—first evaluation. Eur J Cancer 12: 41–45Google Scholar
  48. 48.
    E.O.R.T.C. Brain Tumor Group (1978) Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma—final evaluation. Eur J Cancer 14: 851–856Google Scholar
  49. 49.
    E.O.R.T.C. Brain Tumor Group (1980) Effect of DDMP (2, 4-diamino-5–3’, 4’dichlorophenyl-6-methylpyrimidine) on brain tumors. A phase II study. Europ J Cancer 16: 1639–1640Google Scholar
  50. 50.
    E.O.R.T.C. Brain Tumor Group (1981) Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. J Neurosurg 55: 27–31Google Scholar
  51. 51.
    E.O. R.T.C. Brain Tumor Group (1983) Aberle HG, Brotchi J, Lemaire M, Calliauw L, Chatel M, de Barsy T, Longueville J, de Tribolet N, Bernasconi S, Garfield J, Punt J, Gonzales D, Greiner R, Haefliger LM, Haferkamp G, Hery M, Hildebrand J, Regnier R, Resche F, Bourdin S, Dalesio O, Solbu G: Misonidazole in radiotherapy of supratentorial malignant brain gliomas in adult patients: A randomized double-blind study. Eur J Cancer Clin Oncol 19 /1: 39–42Google Scholar
  52. 52.
    E.O.R.T.C. (1985) Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1aziridinyl)-3,6-dioxodiethylester) in recurring supratentorial malignant brain gliomas—a phase II study. Eur J Cancer Clin Oncol 21 /1: 143–146Google Scholar
  53. 53.
    Erlich SS, Davis RL (1978) Spinal subarachnoid metastasis from primary intracranial glioblastoma multiforme. Cancer 42: 2854–2864PubMedGoogle Scholar
  54. 54.
    Ettinger LJ, Freeman AI, Creaven PJ (1978) Intrathecal methotrexate overdose without neurotoxicity. Cancer 41: 1270–1273PubMedGoogle Scholar
  55. 55.
    Ettinger LJ (1982) Phannacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 50: 440–450Google Scholar
  56. 56.
    Eyre HJ, Sause WT (1985) Treatment of meningeal carcinomatosis with irradiation plus intrathecal methotrexate: A Southern Oncology Group study, ASCO Proc 4: 149Google Scholar
  57. 57.
    Feun LG, Stewart DJ, Maor M, Leavens ME, Savaraj N, Burgess MA, Yung WKA, Benjamin RS (1983) A pilot study of cisdiamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas. J Neuro-Oncol 1: 109–113Google Scholar
  58. 58.
    Feun LG, Yung WKA, Leavens ME. Burgess MA, Obbens EA, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, Bodey GP (1984) A phase II trial of 2,4,diaziridinyl 3,6-bis(carboethoxy amino)1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors. J Neuro-Oncol 2: 13–17Google Scholar
  59. 59.
    Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS (1984) Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799PubMedGoogle Scholar
  60. 60.
    Fewer D, Wilson CB, Boldrey EB, Enot KJ, Powell MR (1972) The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine. JAMA 222 /5: 549–552PubMedGoogle Scholar
  61. 61.
    Friedman HS, Schold SC jr (1985) Rational approaches to the chemotherapy of medulloblastoma. Neurol Clin 3: 843–853PubMedGoogle Scholar
  62. 61.
    Friedman HS, Schold SC jr (1985) Rational approaches to the chemotherapy of medulloblastoma. Neurol Clin 3: 843–853PubMedGoogle Scholar
  63. 63.
    Fulton DS, Levin VA, Gutin PH, Edwards MSB, Seager ML, Stewart J, Wilson B (1982) Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 8: 285291Google Scholar
  64. 64.
    Galicich JH, Sundaresan N, Thaler HT (1980) Surgical treatment of single brain metastasis. Evaluation of results by computerized tomography scanning. J Neurosurg 53: 63–67Google Scholar
  65. 65.
    Gastaut JA, Grisoli F, Vincentelli F, Peragut JC, Maraninchi D, Andrac L, Carcassonne Y (1982) Intracranial malignant lymphoma. In: Hildebrand D, Gangji D (eds) Treatment of neoplastic lesions of the nervous system. Pergamon Press, Oxford New York, pp 149–155Google Scholar
  66. 66.
    Gehan EA, Walker MD (1977) Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 46: 189–195PubMedGoogle Scholar
  67. 67.
    Gerosa MA, di Stefano E, Olivi A (1981) VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: Preliminary report. Surg Neurol 15 /2: 128–134PubMedGoogle Scholar
  68. 68.
    Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J jr, Odom GL, Paoletti P, Ransohoff J II, Robertson JT, Selker RG, Shapiro WR, Smith KR jr, Wilson CB, Strike T (1983) Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67/2: 123132Google Scholar
  69. 69.
    Green SB, Byar DP, Strike TA, Alexander E jr, Brooks WH, Burger PC, Hunt WE, Mealey J jr, Odom GL, Paoletti P, Pistenmaa DA, Ransohoff J II, Robertson JT, Selker RG, Shapiro WR, Smith KR jr (1984) Randomized comparisons of BCNU, streptozotocin, radiosensitizer, and fractionation of radiotherapy in the postoperative treatment of malignant glioma (study 7702). ASCO Proc 3: 260Google Scholar
  70. 70.
    Green SB, Byar DB, Strike TA, Burger PC, Mahaley MS, Mealey J jr, Pistenmaa DA, Ransohoff J II, Robertson JT, Selker RG, Shapiro WR, VanGilder JC (1985) Randomized phase II comparison of PCNU and AZQ for the treatment of primary brain tumors (study 8120). ASCO Proc 4: 143Google Scholar
  71. 71.
    Grisold W, Weiss R, Jellinger K (1984) Klinik and zytologische Diagnostik der meningealen Neoplasien. In: Heyden HW von, Krauseneck P (Hrsg) Hirnmetastasen. Zuckschwerdt, München Bern Wien (Aktuelle Onkol 13, S 85–103 )Google Scholar
  72. 72.
    Groothuis DR, Molnar P, Blasberg RG (1984) Regional blood flow and blood-totissue transport in five brain tumor models. Implications for chemotherapy. In: Brain tumor biology. Karger, Basel, pp 32–153 (Prog Exp Tumor Res, vol 24)Google Scholar
  73. 73.
    Gutin PH, Wilson CB, Kumar ARV, Boldrey EB, Levin V, Powell M, Enot KJ (1975) Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35: 1398–1404Google Scholar
  74. 74.
    Haid M, Khandekar JD, Christ M (1985) Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. Cancer 56: 1311–1315PubMedGoogle Scholar
  75. 75.
    Hande KR, Stein RD, Mcdonough DA, Greco FA, Wolff SN (1982) Effects of high-dose cytarabine. Clin Pharmacol and Therapeutics 31 /5: 669–674Google Scholar
  76. 76.
    Hanson B, Malarme M, Abele R, Regnier R, Hildebrand J (1982) Treatment results in neoplastic meningitis. In: Hildebrand J, Gangji D (eds) Treatment of neoplastic lesions of the nervous system. Pergamon Press, Oxford New York, pp 59–61Google Scholar
  77. 77.
    Hatlevoll R, Lindegaard KF, Hagen S. Kristiansen K, et al. (1985) Combined modality treatment of operated astrocytomas grade 3 and 4. Cancer 56: 41–47PubMedGoogle Scholar
  78. 78.
    Helle TL, Britt RH, Colby TV (1984) Primary lymphoma of the central nervous system. J Neurosurg 60: 94–103PubMedGoogle Scholar
  79. 79.
    Herbst KD, Corder MP, Justice GR (1976) Successful therapy with methotrexate of a multicentric mixed lymphoma of the central nervous system. Cancer 38: 1476–1478PubMedGoogle Scholar
  80. 80.
    Heyden HW von, Krauseneck P (Hrsg) (1984) Hirnmetastasen. Zuckschwerdt, München Bern Wien (Aktuelle Onkologie 13 )Google Scholar
  81. 81.
    Hildebrand J, Brihaye JM, Wagenknecht L, Michel J, Kenis Y (1975) Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors. Eur J Cancer 11: 585–587PubMedGoogle Scholar
  82. 82.
    Hildebrand J, Brihaye J, Wagenknecht JM, Kenis Y (1975) Combination therapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors. Eur J Cancer 11: 585–587PubMedGoogle Scholar
  83. 82.
    a. Hildebrand J, Gangji D (eds) (1982) Treatment of neoplastic lesions of the nervous system. Pergamon Press, Oxford New YorkGoogle Scholar
  84. 83.
    Hildebrand J (1985) Current status of chemotherapy of brain tumours. Prog Exp Tumor Res 29: 152–166PubMedGoogle Scholar
  85. 84.
    Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T (1983) Effect of human leukocyte interferon on malignant brain tumors. Cancer 51 /11: 1976–1981PubMedGoogle Scholar
  86. 85.
    Hochberg FH, Miller G, Schooley RT, et al. (1983) CNS lymphoma related to Epstein-Barr virus. N Engl J Med 309: 745–749Google Scholar
  87. 86.
    Jellinger K, Vole D, Grisold W, Flament H, Vollmer R, Weiss R (1983) Kombinationsbehandlung maligner Gliome. Wien klin Wschr 95 /12: 407–416PubMedGoogle Scholar
  88. 87.
    Jellinger K (1983) Histologische Klassifikation und therapiebedingte Veränderungen. In: Krauseneck P, Mertens HG (Hrsg) Therapie maligner Neoplasien des Gehirns. Perimed, Erlangen, S 15–25Google Scholar
  89. 88.
    Jellinger K (1983) Pathologic effects of chemotherapy. In: Walker MD (ed) Oncology of the nervous system. M Nijhoff, Boston, pp 285–340Google Scholar
  90. 89.
    Jellinger K (1984) Häufigkeit und Charakteristik der zerebralen Karzinommetastasen. In: Heyden HW von, Krauseneck P (HTsg) Hirnmetastasen. Zuckschwerdt, München Bern Wien (Aktuelle Onkologie 13, S 49–79 )Google Scholar
  91. 90.
    Jellinger K (1986) Present limits of conventional treatment for malignant brain tumors. In: Hatanaka H (ed) Boron-neutron capture therapy for tumors. Nishimura, Tokyo, pp 309–349Google Scholar
  92. 90.
    Jellinger K (1986) Present limits of conventional treatment for malignant brain tumors. In: Hatanaka H (ed) Boron-neutron capture therapy for tumors. Nishimura, Tokyo, pp 309–349Google Scholar
  93. 92.
    Jenkin RDT, Simpson WJK, Keen CW (1978) Pineal and suprasellar germinomas. J Neurosurg 48: 99–107PubMedGoogle Scholar
  94. 93.
    Kaplan RS, Wiernik PH (1984) Neurotoxicity of antitumor agents. In: Perry MC (ed) Toxicity of chemotherapy. Grune & Stratton, London, pp 365–433Google Scholar
  95. 94.
    Kessinger A, Lemon HM, Foley JF (1979) VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 63: 511–512PubMedGoogle Scholar
  96. 95.
    Krauseneck P, Mertens HG (Hrsg) (1983) Therapie maligner Neoplasien des Gehirns. Perimed, ErlangenGoogle Scholar
  97. 96.
    Krauseneck, P (1984) Chemotherapie von Hirnmetastasen. In: Heyden HW von, Krauseneck P (Hrsg) Hirnmetastasen. Zuckschwerdt, München Bern Wien. ( Aktuelle Onkologie 13, S 167–179 )Google Scholar
  98. 97.
    Krauseneck P, Mertens HG, Richter E, Schmidt M, Halves E, Bogdahn U, Kappos L, Seybold D (1985) Combined chemotherapy of inoperable and operable malignant gliomas. In: Voth D, Krauseneck P (eds) Chemotherapy of gliomas. De Gruyter, Berlin New York, pp 353–359Google Scholar
  99. 98.
    Krauseneck P, Seybold D, Mertens HG (1985) Pseudo-recurrence in malignant brain tumors. In: Voth D, Krauseneck P (eds) Chemotherapy of gliomas. De Gruyter, Berlin New York, pp 283–290Google Scholar
  100. 99.
    Krauseneck P, Dommasch D, Dienst P, Bogdahn U, Kappos L, Seybold D, Mertens HG (1985) Intrathekale Verträglichkeit von Cytosin-Arabinosid. Verh Dt Ges Neur 3: 500–504Google Scholar
  101. 99a.
    Krauseneck P, Richter E, Dittmann W, Müller HA, Ködel B, Bogdahn U (1986) Radiotherapy in low grade gliomas. Abstr Int Meeting on Brain Oncology, Rennes, p 50Google Scholar
  102. 100.
    Kumar ARV, Renaudin J, Wilson CB, Boldrey EB, Enot KJ, Levin VA (1974) Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study. J Neurosurg 40: 365–371Google Scholar
  103. 101.
    Kunze P, Hoppe W, Riedel C, Döge H (1980) Primäres malignes Lymphom des Zentralnervensystems. Psychiat Neurol Med Psychol 32: 373–381PubMedGoogle Scholar
  104. 102.
    Lee Y, Bigner DD (1985) Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. Neurol Clin 3: 901–917PubMedGoogle Scholar
  105. 103.
    Letendre L, Banks PM, Reese DF, Mill RH, Scanlon PW, Kiely JM (1982) Primary lymphoma of the central nervous system. Cancer 49: 939–943PubMedGoogle Scholar
  106. 104.
    Levin VA, Crafts D, Wilson CB, Kabra P, Hansch C, Boldrey E, Enot J, Neely M (1975) Imidazole carboxamides: Relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors. Cancer Chemo Rep 59 /2: 327–331Google Scholar
  107. 105.
    Levin VA, Crafts DC, Wilson CB, et al. (1976) BCNU and procarbazine treatment for malignant brain tumors. Cancer Treat Rep 60: 243PubMedGoogle Scholar
  108. 106.
    Levin VA, Hoffman WF, Pischer TL, Seager ML, Boldrey EB, Wilson CB (1978) BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 62 /12: 2071–2076PubMedGoogle Scholar
  109. 107.
    Levin VA, Wilson CB, Davis R, Wara WM, Pischer TL, Irwin L (1979) A phase III comparison of BCNU, hydroxyurea and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51: 526–532PubMedGoogle Scholar
  110. 108.
    Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237241Google Scholar
  111. 109.
    Levin VA, Hoffman WF, Heilbron DC, Norman D (1980) Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. J Neurosurg 52: 642–647PubMedGoogle Scholar
  112. 110.
    Levin VA, Vestnys PS, Edwards MS, Wara WM, Fulton D, Barger G, Seager M. Wilson CB (1983) Improvement in survival produced by sequential therapies in the treatment of recurrent medulloblastoma. Cancer 51: 1364–1370Google Scholar
  113. 111.
    Levin VA, Edwards MSB, Gutin PH, Vestnys P, Fulton D, Seager ML, Wilson CB (1984) Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. J Neurosurg 61: 1063–1068PubMedGoogle Scholar
  114. 112.
    Levin VA (1985) Chemotherapy of primary brain tumors. Neurol Clin 3: 855–866PubMedGoogle Scholar
  115. 112.
    Levin VA (1985) Chemotherapy of primary brain tumors. Neurol Clin 3: 855–866PubMedGoogle Scholar
  116. 114.
    Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63: 218–223Google Scholar
  117. 115.
    Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR (1985) Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 3: 490–494PubMedGoogle Scholar
  118. 116.
    Mackintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, Rosenberg SA, Kaplan HS (1982) Central nervous system involvement in non-Hodgkin’s lymphoma: An analysis of 105 cases. Cancer 49: 586–595PubMedGoogle Scholar
  119. 117.
    Mahaley MS jr, Urso MB, Whaley RA, Blue M, Williams TE, Guaspari A, Selker RG (1985) Immunobiology of primary intracranial tumors. J Neurosurg 63: 719–725PubMedGoogle Scholar
  120. 118.
    Mahaley MS (1986) Neuro-oncology review: Radiotherapy, chemotherapy, immunotherapy. ( Unpublished manuscript )Google Scholar
  121. 119.
    Maral J, Poisson M, Pertuiset BF, Mashaly P, Weil M, Jacquillat C, Grillo-Lopez AJ (1985) Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human glioma. J Neuro-Oncol 3: 245–249Google Scholar
  122. 120.
    Markesbery WR, Brooks WH, Gupta GD, Young AB (1978) Treatment for patients with cerebral metastases. Arch Neurol 35: 754–756PubMedGoogle Scholar
  123. 121.
    Marton LJ, et al. (1979) Predictive value of CSF polyamines. Cancer Res 39: 993–997PubMedGoogle Scholar
  124. 122.
    Mazziotta JC (1985) PET scanning: principles and applications. Discussions in Neurosciences 2 /1Google Scholar
  125. 123.
    McKeran RO, Thomas DGT (1980) The clinical study of gliomas. In: Thomas DGT, Graham DI (eds) Brain tumours. Butterworths, London, pp 194–230Google Scholar
  126. 124.
    Mende S, Bleichner F, Stoeter P, Meuret G (1983) Erfolgreiche Behandlung von Hirnmetastasen bei Mammakarzinom mit nicht liquorgängigen Zytostatika and Hormonen. Onkologie 6: 58–61PubMedGoogle Scholar
  127. 125.
    Mertens HG, Bogdahn U, Dommasch D, Krüger H, Wodarz R, Wünsch D (1983) Diagnostik and Therapie cerebrospinaler Manifestationen von Leukosen and malignen Lymphomen. In: Seitz D, Vogel P (Hrsg) Hämoblastosen, Zentrale Motorik, Iatrogene Schäden, Myositiden. Springer, Berlin Heidelberg New York. ( Verh Dt Ges Neur 2, S 49–69 )Google Scholar
  128. 126.
    Nagai M, Arai T, Kohno S, Kohase M (1980) Interferon therapy for malignant brain tumors. In: Kono R, Vilcek J (eds) The clinical potential of interferons. University of Tokyo Press, Tokyo, pp 257–273Google Scholar
  129. 127.
    Nagai M, Arai T (1984) Clinical effect of interferon in malignant brain tumours. Neurosurg Rev 7: 55–64PubMedGoogle Scholar
  130. 128.
    Nagai M, Arai T (1985) Clinical studies on interferon therapy for malignant brain tumors—special reference to the effect of gamma-interferon. Abstracts ann meeting interferon system ( TNO/ISIR ), Clearwater Beach, p 147Google Scholar
  131. 129.
    Nakagawa Y, Hirakawa K, Ueda S, Suzuki K, Fukuma S, Kishida T, Imanishi J, Amagai T (1983) Local administration of interferon for malignant brain tumors. Cancer Treat Reports 67 /9: 833–835Google Scholar
  132. 130.
    Nakagawa Y (1984) Interferon therapy for primary brain tumors (Part I + II). Neurologia Medica-Chirurgica (Tokyo) 24: 83–89, 90–96Google Scholar
  133. 131.
    Neuwelt EA, Glasberg M, Frenkel E, Clark WK (1979) Malignant pineal region tumors. J Neurosurg 51: 597–607PubMedGoogle Scholar
  134. 132.
    Neuwelt EA, Balaban E, Diehl J, Hill S, Frenkel E (1983) Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. Neurosurgery 12: 662–671PubMedGoogle Scholar
  135. 133.
    Newlands ES (1985) Chemotherapy for brain metastases. Prog Exp Tumor Res 29: 167–176PubMedGoogle Scholar
  136. 134.
    Nishio S, Korosue K, Tateishi J, Fukui M, Kitamura K (1982) Ventricular and subarachnoid seeding of intracranial tumors of neuroectodermal origin—A study of 26 consecutive autopsy cases with reference to focal ependymal defect. Clin Neuropathol 1: 83–91PubMedGoogle Scholar
  137. 135.
    Nishio S, Fukui M, Ohta M, Tateishi J, Kitamura K (1983) Spinal subarachnoid seeding from glioblastoma multiforme of the brain stem. Neurol Med Chir 23: 566–570Google Scholar
  138. 136.
    Obbens EAMT, Feun LG, Leavens ME, Savaraj N, Stewart DJ, Gutterman JU (1985) Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies. J Neuro-Oncol 3: 61–67Google Scholar
  139. 137.
    Ommaya AK (1963) Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet ii: 983–984Google Scholar
  140. 138.
    Otsuka S, Handa H, Yamashita J, Suda K, Takeuchi J (1984) Single agent therapy of interferon for brain tumours: Correlation between natural killer activity and clinical course. Acta Neurochirurgica 73: 13–23Google Scholar
  141. 139.
    Owens G, Javid R, Belmusto L, et al. (1965) Intra-arterial vincristine therapy of primary gliomas. Cancer 18: 756PubMedGoogle Scholar
  142. 140.
    Paoletti P (1980) Therapeutic strategy for central nervous system tumors: Present status, criticism and potential. J Neurosurg SCI 28: 51–60Google Scholar
  143. 141.
    Paoletti P, Knerich R, Butti G, Adinolfi D, Locatelli D, Robustelli della Cuna G, Cordero di Montezemolo L, Schiffer D, Soffietti R, Nicolato A, Giunta F, Buoncristiani P, Scamoni C (1983) Italian cooperative study on malignant glial tumor therapy. In: Krauseneck P, Mertens HG (Hrsg) Therapie maligner Neoplasien des Gehirns. Perimed, ErlangenGoogle Scholar
  144. 142.
    Pasquier B, Pasquier D, N’golet A, Panh MH, Couderc P (1979) Le potentiel métastatique des tumeurs primitives du systeme nerveux central. Rev Neurol 135: 263278Google Scholar
  145. 143.
    Patronas NJ, di Chiro G, Brooks RA, et al (1982) Work in progress: (18F) Fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144: 885–889PubMedGoogle Scholar
  146. 144.
    Pierangeli E, Levin VA, Marton LJ (1983) Relationship of brain diffusion and capillary permeability of putrescine (Pu) to CSF levels in brain tumor patients. In: Krauseneck P, Mertens HG (Hrsg) Therapie maligner Neoplasien des Gehirns. Bërimed, Erlangen, S 151–153Google Scholar
  147. 145.
    Posner JB (1980) Chemotherapy and the nervous system. In: Ongerboer de Visser, Bosch DA, van Woerkom-Eykenboom WMH (eds) Neuro-oncology. M Nijhoff, Boston, pp 124–132Google Scholar
  148. 146.
    Posner JP (1982) Treatment of leptomeningeal metastases from solid tumors. In: Hildebrand J, Gangji D (eds) Treatment of neoplastic lesions of the nervous system. Pergamon Press, Oxford New York, pp 57–58Google Scholar
  149. 147.
    Pouillart P, Mathe G, Thy TH, Lheritier J, Poisson M, Huguenin P, Gauthier H, Morin P, Parrot R (1976) Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Cancer 38: 1909–1916PubMedGoogle Scholar
  150. 148.
    Reuther P, Dommasch D, Fuhrmeister U, Krauseneck P, Mertens HG (1983) Intrathekale DTIC-Therapie bei leptomeningealer Melanommetastasierung. In: Krauseneck P, Mertens HG (Hrsg) Therapie maligner Neoplasien des Gehirns. Perimed, Erlangen, S 135–138Google Scholar
  151. 149.
    Rhodes CG, Wise RJS, Gibbs JM et al. (1983) In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14: 614–626PubMedGoogle Scholar
  152. 150.
    Robustelli della Cuna G, Paoletti P, Bertolotti E, Knerich R, Bernardinelli L, Butti G, Baldi M (1979) Combined modality treatment of metastatic central nervous system (CNS) tumors with nitrosourea compounds. In: Paoletti P, Walker MD, Butti G, Knerich R (eds) Multidisciplinary aspects of brain tumor therapy. Elsevier, Amsterdam, pp 283–295Google Scholar
  153. 151.
    Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M,- Glatstein EJ, Wiernik PH, Lichter AS, Bunn PA jr (1982) Carcinomatous leptomeningitis in small cell lung cancer. Medicine 61: 45–53PubMedGoogle Scholar
  154. 152.
    Rosenblum ML, Reynolds AF jr, Smith KA, Rumack BH, Walker MD (1973) Chloroethyl-cyclohexyl-nitrosourea ( CCNU) in the treatment of malignant brain tumors. J Neurosurg 39: 306–314Google Scholar
  155. 153.
    Rosner D, Nemoto T, Pickren J, Lane W (1983) Management of brain metastases from breast cancer by combination chemotherapy. J Neuro-Oncol 1/2: 131–1. 37Google Scholar
  156. 154.
    Rubinstein LJ (1975) The cerebellar medulloblastoma: its origin, differentiation, morphological variants and biological behavior. In: Vinken Pi, Bruyn GW (eds) Tumors of the brain and skull, part 3, vol 9. Elsevier/North-Holland Biomedical Press, New York, pp 167–194Google Scholar
  157. 155.
    Rustin GJS, Newlands ES, Bagshawe KD, Begent RHJ, Crawford SM (1986) Successful management of metastatic and primary germ cell tumors in the brain. Cancer 57: 2108–2113PubMedGoogle Scholar
  158. 156.
    Safdari H, Boluix B, Gros C (1984) Multifocal brain radionecrosis masquerading as tumor dissemination. Surg Neurol 21: 35–41PubMedGoogle Scholar
  159. 157.
    Sano K, Nagai M, Takakura K, Mogami H, Nomura K (1982) Effects of Hu IFN-ß on gliomas. Abstract, the third annual int congr for Interferon Research, Miami, FloridaGoogle Scholar
  160. 158.
    Sapozink MD, Kaplan HS (1983) Intracranial Hodgkin’s disease. Cancer 52: 1301 1307Google Scholar
  161. 159.
    Schindler E (1985) Die Tumoren der Pinealisregion. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  162. 160.
    Schmidt M, Krauseneck P, de l’Espine T, Kappos L (1982) Die Wertigkeit von Lungenfunktionsanalysen in der Diagnostik and Verlaufskontrolle von Zytostatika induzierten interstitiellen Pneumonien. Verhandl Dtsch Ges Inn Med 88: 438–441Google Scholar
  163. 161.
    Schöck LV (1983) Hochdosierte intralumbale Methotrexatgaben. Klinischer Erfahrungsbericht. Onkologie 6 /3: 109–112PubMedGoogle Scholar
  164. 162.
    Schold SC jr, Friedman HS, Bjornsson TD, Folletta JM (1984) Treatment of patients with recurrent primary brain tumors with AZQ. Neurology 34: 615–619PubMedGoogle Scholar
  165. 163.
    Seiler RW (1982) Die undifferenzierten Astrozytome des Großhirns. Springer, Berlin Heidelberg New YorkGoogle Scholar
  166. 164.
    Shapiro WR (1977) High-dose methotrexate in malignant gliomas. Cancer Treat Rep 61: 753–756PubMedGoogle Scholar
  167. 165.
    Shapiro WR (1980) Chemotherapy of metastatic central nervous system carcinoma. In: Weiss L, Gilbert HA, Posner JB (eds) Brain metastasis. Hall, Boston, pp 328–339Google Scholar
  168. 166.
    Shapiro WR (1986) Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13: 38–45PubMedGoogle Scholar
  169. 167.
    Sklansky BD, Mann-Kaplan RS, Reynolds AF jr, Rosenblum ML, Walker MD (1974) 4’-demethyl-epipodophyllotoxin-B-D-thenylidene-glucoside ( PTG) in the treatment of malignant intracranial neoplasms. Cancer 33: 460–467Google Scholar
  170. 168.
    Sorensen SC, Eagan RT, Scott M (1984) Meningeal carcinomatosis in patients with primary breast and lung cancer. Mayo Clin Proc 59: 91–94PubMedGoogle Scholar
  171. 169.
    Stavrou D, Mellert W, Bilzer T, Senekowitsch R, Keiditsch E, Mehraein P (1985) Radioimmunodetection of gliomas by administration of radiolabelled monoclonal antibodies. Experimental data. Anticancer Res 5: 147–156Google Scholar
  172. 170.
    Stewart DJ, Russell N, Atack EA, Quarrington A, Stolbach L (1983) Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of the brain: A case report. Cancer Treat Rep 67: 287–291Google Scholar
  173. 171.
    Stewart DJ, O’Bryan RM, Al-Sarraf M, Costanzi JJ, Oishi N (1983) Phase II study of cisplatin in recurrent astrocytomas in adults: A southwest oncology group study. J Neuro-Oncol 1: 145–147Google Scholar
  174. 172.
    Stewart DJ, Richard MT, Benoit B, Hugenholtz H, Russell N, Dennery J, Peterson E, Grahovac Z, Belanger A, Aitkens S, Young V, Maroun JA (1984) Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neuro-Oncol 2: 29–34Google Scholar
  175. 173.
    Takakura K, Sano K, Hojo S, Hirano A (1982) Metastatic tumors of the central nervous system. Igaku-Shoin, Tokyo New YorkGoogle Scholar
  176. 174.
    Takakura K (1985) Phase II study of recombinant human interferon alpha A (RO 228181) for malignant brain tumors. Abstracts 14th int congr chemotherapy, Kyoto, p 353Google Scholar
  177. 175.
    Takakura K (1985) Intracranial germ cell tumors. Clin Neurosurg 32: 429–444PubMedGoogle Scholar
  178. 176.
    Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, Yamamoto S, Kageyama N, Handa H, Mogami H, Nishimoto A, Uozumi T, Matsutani M, Nomura K (1986) Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64: 5357Google Scholar
  179. 177.
    Talamo TS, Mendelow H (1985) Primary intracranial germinoma with massive ventriculoperitoneal shunt metastases. J Surg Oncol 28: 39–41PubMedGoogle Scholar
  180. 178.
    Taylor SG IV, Nelson L, Baxter D, Rosenbaum C, Sponzo RW, Cunningham TJ, Olson KB, Horton J (1975) Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). Cancer 36: 12691276Google Scholar
  181. 179.
    Theodore WH, Gendelman S (1981) Meningeal carcinomatosis. Arch Neurol 38: 696699Google Scholar
  182. 180.
    Tirelli U, d’Incalci M, Canetta R, Tumolo S, Franchin G, Veronesi A, Galligioni E, Trovo MG, Rossi C, Grigoletto E (1984) Etoposide (VP-16–213) in malignant brain tumors. A phase II study. J Clin Oncol 2: 432–437Google Scholar
  183. 181.
    Tranum BL, Haut A, Rivkin S, Weber E, Quagliana JM, Shaw M, Tucker WG, Smith FE, Samson M, Gottlieb J (1975) A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: A southwest oncology group study. Cancer 35: 11481153Google Scholar
  184. 182.
    Voth D, Hüwel N, Al-Hami S, Kuhnert A (1985) Monotreatment of malignant glioma with a derivate of nitrosourea, ACNU (first results). In: Voth D, Krauseneck P (eds) Chemotherapy of gliomas. De Gruyter, Berlin New York, pp 361–372Google Scholar
  185. 183.
    Vaquero J, Martinez R, Rossi E, Lopez R (1984) Primary cerebral lymphoma: the “ghost tumor”. J Neurosurg 60: 174–176PubMedGoogle Scholar
  186. 184.
    Walker MD, Alexander E jr, Hunt WE, Leventhal CM, Mahaley MS jr, Mealey J jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA (1976) Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44: 655–667PubMedGoogle Scholar
  187. 185.
    Walker MD, Alexander E jr, Hunt WE, MacCarty CS, Mahaley MS jr, Mealey J jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–343PubMedGoogle Scholar
  188. 186.
    Walker MD, Green SB, Byar DP, Alexander E jr, Batzdorf U, Brook WH, Hunt WE, MacCarty CS, Mahaley MS jr, Mealey J jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N England J Med 303: 1323–1329Google Scholar
  189. 187.
    Wasserstrom WR, Glass PJ, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 49: 759–772PubMedGoogle Scholar
  190. 188.
    Wilson CB, Boldrey EB, Enot KJ (1970) 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC409962) in the treatment of brain tumors. Cancer Chemo Rep 54/4: 273–281Google Scholar
  191. 189.
    Yap HY, Yap BS, Rasmussen S, Levens M, Hortobagyi GN, Blumenschein GR (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 49: 219–222Google Scholar
  192. 190.
    Young RC, Waler MD, Canellos GP, Schein PS, Chabner BA, DeVita VT (1973) Initial clinical trials with methyl-CCNU 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1 - nitrosourea ( MeCCNU ). Cancer 31: 1164–1169Google Scholar
  193. 191.
    Zülch KJ (1979) Histological typing of tumours of the central nervous system. WHO, GenfGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1987

Authors and Affiliations

  • P. Krauseneck
    • 1
  • H. G. Mertens
    • 1
  1. 1.Department of NeurologyUniversity of WürzburgFederal Republic of Germany

Personalised recommendations